Related references
Note: Only part of the references are listed.Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase I trials as valid therapeutic options for patients with cancer
Jacob J. Adashek et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Dejan Juric et al.
JAMA ONCOLOGY (2019)
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
Daphne Day et al.
JNCI CANCER SPECTRUM (2019)
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen et al.
BRITISH JOURNAL OF CANCER (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
Brent O'Carrigan et al.
BRITISH JOURNAL OF CANCER (2018)
Accelerating anticancer drug development - opportunities and trade-offs
Sharyl J. Nass et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms AMeta-analysis
Maria Schwaederle et al.
JAMA ONCOLOGY (2016)
Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Prasanth Ganesan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors
David Olmos et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A new, simple and objective prognostic score for phase I cancer patients
L. M. Fussenich et al.
EUROPEAN JOURNAL OF CANCER (2011)
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
A. T. Brunetto et al.
BRITISH JOURNAL OF CANCER (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anticancer drug development: the grand challenges
William N. Hait
NATURE REVIEWS DRUG DISCOVERY (2010)
Survival of Patients in a Phase 1 Clinic The M. D. Anderson Cancer Center Experience
Jennifer Wheler et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer:: Predictive value of centrally reviewed expression of estrogen and progesterone receptors -: International Breast Cancer Study Group
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
